甲磺酸阿帕替尼联合化疗对晚期乳腺癌患者CEA、CA125水平的影响  

Effects of Apatinib Mesylate Combined with Chemotherapy on CEA and CA125 Levels in Patients with Advanced Breast Cancer

作　　者：孙丽[1] SUN Li(Xuzhou Central Hospital,Xuzhou,Jiangsu 221009,China)

机构地区：[1]徐州市中心医院,江苏徐州221009

出　　处：《大医生》2019年第22期30-32,共3页Doctor

摘　　要：目的研究甲磺酸阿帕替尼联合化疗对晚期乳腺癌患者糖类抗原125(carbohydrate antigen,CA125)、癌胚抗原(carcinoembryonic antigen,CEA)水平的影响。方法回顾性分析徐州市中心医院2016年6月至2019年1月收治的40例晚期乳腺癌患者,均采用甲磺酸阿帕替尼联合化疗。分析其CEA、CA125水平变化、疗效和不良反应。结果本组40例患者CBR为50.00%,ORR为10.00%,mPFS为6个月;与治疗前相比,治疗后血清CEA、CA125水平均降低(P<0.05);患者经联合化疗具有良好耐受性。结论甲磺酸阿帕替尼联合化疗可有效延长晚期乳腺癌患者生存期,降低血清CEA、CA125水平,患者基本可以耐受不良反应。Objective To study the effects of apatinib mesylate combined with chemotherapy on CEA and CA125 levels in patients with advanced breast cancer.Methods Retrospective analysis was performed on 40 patients with advanced breast cancer admitted to xuzhou central hospital from June 2016 to January 2019,all of whom received apatinib mesylate combined with chemotherapy.Changes in CEA and CA125 levels,efficacy and adverse reactions were analyzed.Results Totally 40 patients in this group had a CBR of 50.0%.Compared with before treatment,serum CEA and CA125 levels were reduced(P<0.05).Conclusion Apatinib mesylate combined with chemotherapy can effectively alleviate advanced breast cancer patients,reduce serum CEA and CA125 levels,and adverse reactions can basically tolerate them.

关 键 词：晚期乳腺癌 甲磺酸阿帕替尼 化疗 

分 类 号：R73[医药卫生—肿瘤]